了解Clostridioides difficile感染和治疗的流行病学发展:全球视角
Crystal Liu1, Tanya Monaghan2, Abbas Yadegar3
1Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Antibiotics (Basel, Switzerland)
|July 29, 2023
概括
困难菌感染 (CDI) 是一个全球性的威胁,新兴的菌株导致严重的后果. 了解C. difficile流行病学对于全球有效的预防和治疗策略至关重要.
科学领域:
- 传染性疾病 传染性疾病
- 流行病学 流行病学
- 微生物学 微生物学
背景情况:
- 困难菌仍然是一个重要的全球公共卫生问题.
- 超病毒性菌株的出现,如 ribotype 027 和其他 (014/020, 017, 056, 106, 078/126) 导致C. difficile感染 (CDI) 的健康结果不佳.
- 这些菌株在地理分布,遗传学,毒性和抗菌素易感性方面表现出差异,影响疾病进展和治疗疗效.
研究的目的:
- 审查过去十年中C. difficile流行病学的发展情况.
- 为了突出全球重要的C. difficile核型.
- 讨论目前和新兴的CDI治疗策略.
主要方法:
- 关于C. difficile流行病学的最新研究的文献综述.
- 对流行的C. difficile核型及其特征的数据分析.
- 综合了关于CDI治疗进展的信息.
主要成果:
- 困难菌的流行病学是动态的,普遍存在的核型变化.
- 某些核糖类型 (例如014/020,017,056,106,078/126) 与严重的CDI结局有关.
- 监控挑战阻碍了准确的全球负担估计,特别是在低收入和中等收入国家.
结论:
- 对C. difficile的持续流行病学监测对于公共健康至关重要.
- 了解菌株变异是管理CDI的关键.
- 需要不断发展的治疗方法来应对C. difficile感染的变化.
相关概念视频
01:30Development of Antibiotic Resistance
41
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
41
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
4.3K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
4.3K
01:22Healthcare Associated Infections II: Preventive Measures
2.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.7K
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
158
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
158
01:17Drugs for Treatment of Diarrhea-Predominant IBS
214
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
214
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
456
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
456